Table 2.
Univariate and multivariate analyses for OS
| Characteristics | Univariate analysis OS | Multivariate analysis OS | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Sex | 0.16 | |||
| Female | 1 | |||
| Male | 0.80 (0.59–1.09) | |||
| Age | 0.18 | |||
| ≤ 70 years | 0.84 (0.66–1.08) | |||
| > 70 years | 1 | |||
| Etiology | 0.75 | |||
| Viral | 0.96 (0.75–1.23) | |||
| Non-viral | 1 | |||
| BCLC | 0.03 | 0.79 | ||
| B | 0.76 (0.59–0.98) | 0.96 (0.72–1.28) | ||
| C | 1 | 1 | ||
| AFP | < 0.01 | < 0.01 | ||
| < 400 ng/mL | 0.47 (0.36–0.62) | 0.65 (0.38–0.85) | ||
| ≥ 400 ng/mL | 1 | 1 | ||
| Child–Pugh | < 0.01 | |||
| A | 0.10 (0.05–0.20) | |||
| B | 1 | |||
| NLR | < 0.01 | < 0.01 | ||
| < 3 | 0.56 (0.43–0.73) | 0.67 (0.42–0.87) | ||
| ≥ 3 | 1 | 1 | ||
| EHD | 0.77 | |||
| Yes | 1 | |||
| No | 0.96 (0.75–1.24) | |||
| ALBI | < 0.01 | < 0.01 | ||
| 1 | 0.11 (0.06–0.19) | 0.13 (0.07–0.22) | ||
| 2 | 1 | 1 | ||
| PS | 0.01 | |||
| ≤ 1 | 0.24 (0.07–0.76) | |||
| > 1 | 1 | |||
| PVT | < 0.01 | |||
| Yes | 1 | |||
| No | 0.53 (0.39–0.71) | |||
| Decreased appetite | < 0.01 | |||
| Yes | 1 | |||
| No | 0.59 (0.43–0.80) | |||
| Decreased appetite | < 0.01 | < 0.01 | ||
| G < 2 | 0.37 (0.23–0.60) | 1 | ||
| G ≥ 2 | 1 | 0.60 (0.13–0.90) | ||
| Fatigue | < 0.01 | |||
| Yes | 1 | |||
| No | 0.57 (0.43–0.77) | |||
| Fatigue | < 0.01 | 0.21 | ||
| G < 2 | 0.50 (0.31–0.80) | 0.84 (0.47–1.07) | ||
| G ≥ 2 | 1 | 1 | ||
| Proteinuria | 0.25 | |||
| Yes | 0.86 (0.66–1.11) | |||
| No | 1 | |||
| Proteinuria | 0.23 | |||
| G < 2 | 1 | |||
| G ≥ 2 | 0.83 (0.61–1.13) | |||
| Hypertension | < 0.01 | 0.10 | ||
| Yes | 0.69 (0.53–0.89) | 0.77 (0.57–1.05) | ||
| No | 1 | 1 | ||
| Hypertension | 0.03 | |||
| G < 2 | 1 | |||
| G ≥ 2 | 0.72 (0.54–0.97) | |||
| Immunotoxicity | 0.02 | |||
| Yes | 1 | |||
| No | 0.66 (0.46–0.94) | |||
| Immunotoxicity | < 0.01 | 0.04 | ||
| G < 2 | 0.45 (0.27–0.77) | 0.70 (0.24–0.99) | ||
| G ≥ 2 | 1 | 1 | ||
| Diarrhea | 0.46 | |||
| Yes | 0.85 (0.56–1.30) | |||
| No | 1 | |||
| Diarrhea | 0.12 | |||
| G < 2 | 0.50 (0.21–1.18) | |||
| G ≥ 2 | 1 | |||
| Hypothyroidism | 0.47 | |||
| Yes | 0.83 (0.51–1.37) | |||
| No | 1 | |||
| Hypothyroidism | 0.91 | |||
| G < 2 | 1 | |||
| G ≥ 2 | 0.97 (0.52–1.80) | |||
| Other toxicity | 0.56 | |||
| Yes | 1 | |||
| No | 0.92 (0.68–1.23) | |||
| Other toxicity | 0.10 | |||
| G < 2 | 0.75 (0.53–1.06) | |||
| G ≥ 2 | 1 | |||
p < 0.05 are reported in bold
AFP alpha-feto-protein, ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, EHD extrahepatic disease, G grade, NLR neutrophil-lymphocyte ratio, OS overall survival, PS performance status, PVT portal vein thrombosis